Bispecific binding agents binding to CLDN18.2 and CD3
The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English |
Published |
29.08.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer. |
---|---|
Bibliography: | Application Number: US202218062465 |